Abstract
A large body of evidence has described the antioxidant properties of phytochemicals such as PolyPhenols (PP) in different in vitro and ex vivo models. PP have been shown to scavenge oxygen and nitrogen derived free radicals, modulating antioxidant enzymes and cellular redox transcription factors. Dietary intervention studies have shown that consumption of plant foods modulate plasma Non Enzymatic Antioxidant Capacity (NEAC), biomarker of endogenous antioxidant network, in human subjects. However the identification of the molecules responsible for this effect is far to be obtained and evidences of an antioxidant in vivo action of PP are contrasting. There is a clear discrepancy between PP concentration in body fluids and the extent of increase of plasma NEAC. The low degree of absorption and the extensive metabolism of PP within the body have raised questions about their contribution to the in vivo antioxidant network. The available evidence from human intervention studies on the role of plant foods as modulators of plasma/serum NEAC and the involvement of PP will be presented and critically discussed.
Keywords: Human, non enzymatic antioxidant capacity (NEAC), oxidative stress, plant foods, polyphenols, total antioxidant capacity (TAC), PolyPhenols (PP), scavenge, Free Radical Species (FRS), inflammation, respiratory burst, diabetes, neuro-degenerative diseases, cardiovascular diseases, cancer
Current Topics in Medicinal Chemistry
Title: Modulation of Plasma Non Enzimatic Antioxidant Capacity (NEAC) by Plant Foods: the Role of Polyphenol
Volume: 11 Issue: 14
Author(s): M. Serafini, C. Miglio, I. Peluso and T. Petrosino
Affiliation:
Keywords: Human, non enzymatic antioxidant capacity (NEAC), oxidative stress, plant foods, polyphenols, total antioxidant capacity (TAC), PolyPhenols (PP), scavenge, Free Radical Species (FRS), inflammation, respiratory burst, diabetes, neuro-degenerative diseases, cardiovascular diseases, cancer
Abstract: A large body of evidence has described the antioxidant properties of phytochemicals such as PolyPhenols (PP) in different in vitro and ex vivo models. PP have been shown to scavenge oxygen and nitrogen derived free radicals, modulating antioxidant enzymes and cellular redox transcription factors. Dietary intervention studies have shown that consumption of plant foods modulate plasma Non Enzymatic Antioxidant Capacity (NEAC), biomarker of endogenous antioxidant network, in human subjects. However the identification of the molecules responsible for this effect is far to be obtained and evidences of an antioxidant in vivo action of PP are contrasting. There is a clear discrepancy between PP concentration in body fluids and the extent of increase of plasma NEAC. The low degree of absorption and the extensive metabolism of PP within the body have raised questions about their contribution to the in vivo antioxidant network. The available evidence from human intervention studies on the role of plant foods as modulators of plasma/serum NEAC and the involvement of PP will be presented and critically discussed.
Export Options
About this article
Cite this article as:
Serafini M., Miglio C., Peluso I. and Petrosino T., Modulation of Plasma Non Enzimatic Antioxidant Capacity (NEAC) by Plant Foods: the Role of Polyphenol, Current Topics in Medicinal Chemistry 2011; 11 (14) . https://dx.doi.org/10.2174/156802611796235125
DOI https://dx.doi.org/10.2174/156802611796235125 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
24-Hour Blood Pressure Control – A Predictor for Clinical Outcomes
Current Hypertension Reviews Vulnerable Plaque and Inflammation: Potential Clinical Strategies
Current Pharmaceutical Design Evaluation of Clinical Efficacy of Fasudil for the Treatment of Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery Mitochondria-Targeted Drugs
Current Molecular Pharmacology Long Noncoding RNA OIP5-AS1 Overexpression Promotes Viability and Inhibits High Glucose-Induced Oxidative Stress of Cardiomyocytes by Targeting MicroRNA-34a/SIRT1 Axis in Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Impact of Chronic Kidney Disease on Risk for Vascular Events
Current Vascular Pharmacology A Systematic Review of Lifestyle Modification and Glucose Intolerance in the Prevention of Type 2 Diabetes
Current Diabetes Reviews Lipid-based Vesicular Nanocargoes as Nanotherapeutic Targets for the Effective Management of Rheumatoid Arthritis
Recent Patents on Anti-Infective Drug Discovery The Role of Autophagy in the Pathogenesis of Ischemic Stroke
Current Neuropharmacology Sarcolemmal K<sub>ATP</sub> Channel Modulators and Cardiac Arrhythmias
Current Medicinal Chemistry Diagnosis and Management of Endocrine Hypertension in Children and Adolescents
Current Pharmaceutical Design Wave Intensity Analysis in the Human Coronary Circulation in Health and Disease
Current Cardiology Reviews Combination of Captopril with Gliclazide Decreases Vascular and Renal Complications and Improves Glycemic Control in Rats with Streptozotocin- Induced Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Energy Remodeling, Mitochondrial Disorder and Heart Failure
Current Pharmaceutical Design State of the Art of Nanobiotechnology Applications in Neglected Diseases
Current Nanoscience Circulating Levels of Soluble Angiogenic Factors in Multiple Myeloma: Correlation with Parameters of Disease Activity and Prognosis
Current Angiogenesis (Discontinued) Stem Cells and Translational Medicine: From Research to Clinical Procedures
Current Tissue Engineering (Discontinued) The Effects of Pemafibrate in Japanese Patients with Type 2 Diabetes Receiving HMG-CoA Reductase Inhibitors
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-Angiogenic Effects of Resveratrol on Cerebral Angiogenesis
Current Neurovascular Research Therapeutic Angiogenesis in Ischemic Heart Disease: Gene or Recombinant Vascular Growth Factor Protein Therapy?
Current Gene Therapy